Table 3.

Clinicopathologic features of patients diagnosed with colorectal liver metastases showing high and low Smad ubiquitination regulatory factor 2 (Smurf2) expression.

	Smurf2 expression		P value
	High (n = 49)	Low (n = 17)
Age at primary surgery (years), Median (range)	68 (46–84)	69 (50–79)	0.9356
Gender, Male/Female	32/17	12/5	0.7726
Site of tumor, Colon/Rectum	31/18	9/8	0.5668
Site of tumor, Right/Left/Rectum	15/16/18	4/5/8	0.7397
Degree of differentiation, tub, pap/por, muc	47/2	15/2	0.2714
Ly, 0–1/2–3	40 / 9	15 / 2	0.7145
V, 0–1/2–3	24/25	7/10	0.7786
T stage (8th edition), 1/2/3/4	0/1/25/23	1/1/9/6	0.2342
Lymph node metastasis, + / −	29/20	10/7	1.0000
CEA before hepatectomy, median (range)	50.7 ± 170.0	947.2 ± 288.6	0.0094
CA19-9, median (range)	129.9 ± 497.7	1825.8 ± 845.0	0.0886
KRAS mutation, Wild/Mutant	9/4	9/7	0.7021
Adjuvant chemotherapy, + / −	36/13	13/4	1.0000
Interval to liver metastasis (months), mean ± SD	5.6 ± 1.5	5.3 ± 2.6	0.9106
Timing of metastasis, Synchronous/metachronous	29/20	10/7	1.0000
Number of liver metastatic tumors, mean ± SD	3.0 ± 0.4	2.6 ± 0.7	0.6250
Number of liver metastatic tumors, Solitary/Multiple	17/32	6/11	1.0000
Size of liver metastatic tumors (cm), mean ± SD	3.6 ± 0.4	4.1 ± 0.6	0.4674
Site of liver metastasis, Unilateral/Bilateral	17/14	20/15	1.0000
Hepatectomy, Minor/Major	45/4	11/6	0.0143
H factor, H1/H2/H3	33/15/1	10/7/0	0.6689
Extrahepatic metastases, + / −	9/40	3/14	1.0000
Resection margin, R0/R1/R2	27/14/8	8/6/3	0.8372
Adjuvant chemotherapy after hepatectomy, + / −	36/13	13/4	1.0000
Recurrence after hepatectomy (all organs), + / −	38/11	16/1	0.1632
Intrahepatic recurrence after hepatectomy, + / −  Number of tumors, mean ± SD	26/23 2.4 ± 0.5	10/7 3.8 ± 0.8	0.78100.1185
Recurrence in multiple organs, + / −	6/43	15/2	1.0000
Repeat resection (all organs), + / −	24/14	6/10	0.1332
Repeat hepatectomy, + / −	13/13	2/8	0.1422

CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19–9; KRAS, Kirsten rat sarcoma viral oncogene.